Literature DB >> 26648603

Choosing a combined oral contraceptive pill.

Mary Stewart1, Kirsten Black2.   

Abstract

The combined oral contraceptive pill is an effective contraceptive method which can also offer other benefits. However, other contraceptive options should be discussed. If the pill is the chosen method, prescribe a pill with the lowest effective dose of oestrogen and progestogen. Pills containing levonorgestrel or norethisterone in combination with ethinyloestradiol 35 microgram or less are considered first-line. They are effective if taken correctly, have a relatively low risk of venous thromboembolism, and are listed on the Pharmaceutical Benefits Scheme. The pill is usually taken in a monthly cycle. Some women may prefer an extended pill regimen with fewer or no inactive pills.

Entities:  

Keywords:  combined oral contraceptives; oestrogens; progestogens; venous thromboembolism

Year:  2015        PMID: 26648603      PMCID: PMC4654044          DOI: 10.18773/austprescr.2015.002

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  31 in total

Review 1.  Efficacy of contraceptive methods: A review of the literature.

Authors:  Diana Mansour; Pirjo Inki; Kristina Gemzell-Danielsson
Journal:  Eur J Contracept Reprod Health Care       Date:  2010-02       Impact factor: 1.848

2.  Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.

Authors:  M Raps; F Rosendaal; B Ballieux; J Rosing; S Thomassen; F Helmerhorst; H van Vliet
Journal:  J Thromb Haemost       Date:  2013-05       Impact factor: 5.824

3.  Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.

Authors:  Jeffrey T Jensen; Susanne Parke; Uwe Mellinger; Andrea Machlitt; Ian S Fraser
Journal:  Obstet Gynecol       Date:  2011-04       Impact factor: 7.661

4.  Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.

Authors:  Jürgen Dinger; Thai Do Minh; Nina Buttmann; Kristina Bardenheuer
Journal:  Obstet Gynecol       Date:  2011-01       Impact factor: 7.661

Review 5.  20 µg versus >20 µg estrogen combined oral contraceptives for contraception.

Authors:  Maria F Gallo; Kavita Nanda; David A Grimes; Laureen M Lopez; Kenneth F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

Review 6.  Combined oral contraceptive pills for treatment of acne.

Authors:  Ayodele O Arowojolu; Maria F Gallo; Laureen M Lopez; David A Grimes
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

7.  Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study.

Authors:  Philip C Hannaford; Lisa Iversen; Tatiana V Macfarlane; Alison M Elliott; Valerie Angus; Amanda J Lee
Journal:  BMJ       Date:  2010-03-11

8.  Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.

Authors:  Jürgen Dinger; Kristina Bardenheuer; Klaas Heinemann
Journal:  Contraception       Date:  2014-02-04       Impact factor: 3.375

9.  Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study.

Authors:  G Macìas; G S Merki-Feld; S Parke; U Mellinger; M Serrani
Journal:  J Obstet Gynaecol       Date:  2013-08       Impact factor: 1.246

Review 10.  An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest.

Authors:  Franca Fruzzetti; Florence Trémollieres; Johannes Bitzer
Journal:  Gynecol Endocrinol       Date:  2012-04-02       Impact factor: 2.260

View more
  7 in total

1.  Norethisterone Related Drug Induced Liver Injury: A Series of 3 Cases.

Authors:  Narendra S Choudhary; Vijay Bodh; Shraddha Chaudhari; Neeraj Saraf; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2017-04-21

2.  The Effect of the Menstrual Cycle and Oral Contraceptives on Acute Responses and Chronic Adaptations to Resistance Training: A Systematic Review of the Literature.

Authors:  Belinda Thompson; Ashley Almarjawi; Dean Sculley; Xanne Janse de Jonge
Journal:  Sports Med       Date:  2020-01       Impact factor: 11.136

3.  Effects of oral contraceptive use on muscle strength, muscle thickness, and fiber size and composition in young women undergoing 12 weeks of strength training: a cohort study.

Authors:  Eun-Sook Sung; Ahreum Han; Timo Hinrichs; Matthias Vorgerd; Petra Platen
Journal:  BMC Womens Health       Date:  2022-05-10       Impact factor: 2.742

4.  The Effects of Oral Contraceptives on Exercise Performance in Women: A Systematic Review and Meta-analysis.

Authors:  Kirsty J Elliott-Sale; Kelly L McNulty; Paul Ansdell; Stuart Goodall; Kirsty M Hicks; Kevin Thomas; Paul A Swinton; Eimear Dolan
Journal:  Sports Med       Date:  2020-10       Impact factor: 11.136

5.  The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases.

Authors:  Santosh Sanagapalli; Yanna Ko; Viraj Kariyawasam; Siew C Ng; Whitney Tang; Hithanadura Janaka de Silva; Minhu Chen; Kaichun Wu; Satimai Aniwan; Ka Kei Ng; David Ong; Qin Ouyang; Ida Hilmi; Marcellus Simadibrata; Pises Pisespongsa; Saranya Gopikrishna; Rupert W Leong
Journal:  Intest Res       Date:  2018-07-27

Review 6.  Effects of orally administered hormonal contraceptives on the musculoskeletal system of healthy premenopausal women-A systematic review.

Authors:  Claudia Römer; Julia Czupajllo; Bernd Wolfarth; Markus H Lerchbaumer; Kirsten Legerlotz
Journal:  Health Sci Rep       Date:  2022-08-10

7.  Development of Hormonal Intravaginal Rings: Technology and Challenges.

Authors:  Fojan Rafiei; Hadi Tabesh; Shayan Farzad; Farah Farzaneh; Maryam Rezaei; Fateme Hosseinzade; Khosrow Mottaghy
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-07-13       Impact factor: 2.915

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.